Veeva Systems delivered a solid Q3 FY2025 performance, underscoring the company’s leadership in cloud-based software for the life sciences industry. Revenue of $699.2 million grew 13.4% year over year and 3.4% quarter over quarter, driven by sustained demand for Veeva’s suite of cloud solutions (CRM, Vault, OpenData, and related data analytics). Gross margin remained highly attractive at ~75.1%, with operating margin near 26.0% and net margin around 26.6%, reflecting a scalable subscription model and disciplined cost management. Cash flow remains robust, with CFO of $164.1 million and a cash balance of roughly $1.046 billion, while the balance sheet shows substantial liquidity from cash and short-term investments (~$5.063 billion) and minimal net debt (~-$0.973 billion). The quarter also featured a meaningful deferred revenue balance, indicative of strong recurring revenue and long-term customer engagements. Management commentary was not available in the provided data, limiting quotes from the earnings call; accordingly, the executive summary focuses on quantified outcomes and the implications for growth, profitability, and capital allocation. The relative valuation remains elevated versus broader software peers, underscoring the market’s confidence in Veeva’s growth trajectory and its dominant position in life sciences cloud software.